Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.
Autonomix said it is on track to commence enrollment this month.
The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.
Autonomix Medical shares were 14% lower in recent trading.
Price: 1.38, Change: -0.24, Percent Change: -14.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.